Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Liabilities from Discontinued Operations (2024)

Indivior Pharmaceuticals has reported Liabilities from Discontinued Operations over the past 1 years, most recently at 205000000.0 for Q4 2024.

  • For Q4 2024, Liabilities from Discontinued Operations changed N/A year-over-year to 205000000.0; the TTM value through Dec 2024 reached 205000000.0, changed N/A, while the annual FY2024 figure was 205000000.0, N/A changed from the prior year.
  • Liabilities from Discontinued Operations for Q4 2024 was 205000000.0 at Indivior Pharmaceuticals, down from 167000000.0 in the prior quarter.
  • Over five years, Liabilities from Discontinued Operations peaked at 121000000.0 in Q2 2024 and troughed at 205000000.0 in Q4 2024.